Treatment of Complications from Immune Checkpoint Inhibition in Patients with Lung Cancer

Immune checkpoint inhibitors have revolutionized the management of advanced NSCLC. With the intention of generating an anti-tumor immune response, ICIs can also lead to inflammatory side effects involving a wide variety of organs in the body, termed immune-related adverse events. Although no prospec...

Descripción completa

Detalles Bibliográficos
Autores principales: Wills, Beatriz, Brahmer, Julie R., Naidoo, Jarushka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2018
Materias:
Lung Cancer (HA Wakelee, Section Editor)
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7102206/
https://www.ncbi.nlm.nih.gov/pubmed/30101402
http://dx.doi.org/10.1007/s11864-018-0562-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7102206/
https://www.ncbi.nlm.nih.gov/pubmed/30101402
http://dx.doi.org/10.1007/s11864-018-0562-9

Ejemplares similares